Bacterial DnaK reduces the activity of anti-cancer drugs cisplatin and 5FU.

Francesca BenedettiEmmanuel F MongodinJonathan H BadgerArshi MunawwarAshley CelliniWeirong YuanGiovannino SilvestriCarl N KrausSimone MariniChozha V RathinamMarco SalemiHervé TettelinRobert C GalloDavide Zella

Published in: Journal of translational medicine (2024)

Our findings offer a practical framework for designing and implementing novel personalized anti-cancer strategies by targeting specific bacterial DnaKs in patients with poor response to chemotherapy, underscoring the potential for microbiome-based personalized cancer therapies.

Keyphrases

papillary thyroid
squamous cell
quality improvement
squamous cell carcinoma
climate change
young adults